BMY Bristol Myers Squibb Loading...

From GILD earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
21:30
Feb 10 ◎
Cindy Peretti Executive Vice President of KITE, Gilead Sciences, Inc. GILD Q4 FY25 call
Gilead expects KITE cell therapy sales to decline ~10% in 2026, in part due to more patients going into clinical trials for competitor CAR-Ts. — Competing clinical trial sites are diverting patients away from KITE's commercial products, a unique headwind that may persist until newer KITE products launch.
BMY
HIGH

About BMY Analyst Coverage

Buzzberg tracks BMY (Bristol Myers Squibb) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 1 total trade idea tracked. Latest voices: Cindy Peretti.